Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
ARDX submitted a Form 144 notice relating to Common Stock tied to the vesting of restricted stock units. The excerpt shows 5,355 shares associated with vesting on 02/19/2026, with broker Morgan Stanley Smith Barney LLC listed.
Ardelyx filed a Form 144 notice to sell 7,771 shares of common stock following the vesting of restricted stock units on 02/19/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares relate to services rendered.
ARDX submitted a Form 144 notice regarding Common Stock. The filing lists a 3,000 share entry associated with a broker and a separate 6,216 share item tied to the vesting of restricted stock units dated 02/19/2026.
The broker named is Morgan Stanley Smith Barney LLC; the vesting is shown as for services rendered.
Ardelyx, Inc. filed its Form 10-K describing a commercial-stage biopharma business built around tenapanor, marketed as IBSRELA for IBS‑C and XPHOZAH for dialysis patients with hyperphosphatemia. The company is expanding tenapanor into chronic idiopathic constipation through the Phase 3 ACCEL trial and advancing a next‑generation NHE3 inhibitor, RDX10531.
The filing highlights that XPHOZAH’s inclusion in the ESRD Prospective Payment System on January 1, 2025 eliminated Medicare Part D coverage, causing a negative and material impact on 2025 XPHOZAH revenue and pointing to slower future growth. Ardelyx reports cash, cash equivalents and short‑term investments of $264.7 million and $200 million of term debt outstanding as of December 31, 2025, plus an unused at‑the‑market equity program of up to $100 million. Management emphasizes ongoing losses since inception, reliance on growing IBSRELA and XPHOZAH sales, and potential need for additional financing while it continues to invest in commercialization and pipeline development.
Ardelyx reported full-year 2025 revenue of $407.3 million, up from $333.6 million in 2024, driven by strong growth in its IBSRELA and XPHOZAH franchises. IBSRELA revenue rose to $274.2 million, a 73% increase from $158.3 million, while XPHOZAH revenue was $103.6 million, down from $160.9 million.
The company posted a 2025 net loss of $61.6 million, or $(0.26) per share, compared with a net loss of $39.1 million in 2024, as R&D expenses grew to $71.5 million and SG&A reached $337.2 million. Cash, cash equivalents and short-term investments were $264.7 million as of December 31, 2025.
For 2026, Ardelyx guides to product revenue of $520–$550 million, including IBSRELA revenue of $410–$430 million and XPHOZAH revenue of $110–$120 million, with operating expenses up to $520 million. The company is advancing a Phase 3 ACCEL trial for tenapanor in chronic idiopathic constipation and preparing an IND submission in the second half of 2026 for next‑generation NHE3 inhibitor RDX10531.
The Vanguard Group filed an amended ownership report showing it holds a significant stake in Ardelyx Inc common stock. Vanguard reports beneficial ownership of 18,979,483 shares, representing 7.81% of the outstanding common stock.
Vanguard has no sole voting or dispositive power over these shares, but reports shared voting power over 1,958,646 shares and shared dispositive power over 18,979,483 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Ardelyx.
The filing also notes that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries or business divisions that pursue the same investment strategies may report beneficial ownership separately from The Vanguard Group.
Ardelyx, Inc. reported that Senior Vice President of Finance Joseph James Reilly received new equity awards on January 23, 2026. He was granted 46,200 restricted stock units (RSUs), which each convert into one share of common stock upon vesting, at a grant price of $0. He also received a stock option for 69,360 shares of common stock at an exercise price of $7.77 per share, with the option vesting in 48 equal monthly installments starting January 23, 2026, conditioned on continued service. Following these awards, he beneficially owns 156,781 shares of Ardelyx common stock, which includes 1,667 shares acquired through the company’s employee stock purchase plan on August 31, 2025.
Ardelyx, Inc. reported that Chief Business Officer Mike Kelliher received new equity awards on January 23, 2026. He was granted 103,080 restricted stock units, each convertible into one share of common stock upon vesting. He also received a stock option for 154,625 shares of common stock at an exercise price of $7.77 per share, vesting in 48 equal monthly installments starting January 23, 2026, subject to continued service. Following these awards, he directly beneficially owned 374,261 shares of Ardelyx common stock.
Ardelyx, Inc. chief financial officer Susan Hohenleitner reported equity awards consisting of common stock and stock options. On January 23, 2026, she received 85,670 shares of common stock at a price of $0, described as restricted stock units that convert into one share of common stock per unit upon vesting. Following this grant, she beneficially owned 232,566 shares of Ardelyx common stock directly.
On the same date, she was also granted a stock option for 128,505 shares with an exercise price of $7.77 per share and an expiration date of January 23, 2036. The option becomes exercisable as it vests in 48 equal monthly installments starting on January 23, 2026, conditioned on her continued employment or service with Ardelyx.
Ardelyx, Inc. Chief Commercial Officer Eric Duane Foster reported new equity awards and updated his share holdings. On January 23, 2026, he received 137,945 shares of Common Stock for no cash consideration in the form of restricted stock units, each RSU converting into one share upon vesting. Following this grant, he beneficially owned 436,409 shares of Common Stock, which include 2,780 shares previously purchased under the Ardelyx Employee Stock Purchase Plan on August 31, 2025. He was also granted a stock option for 206,915 shares of Common Stock with a $7.77 exercise price, vesting in 48 equal monthly installments beginning on January 23, 2026, contingent on his continued employment.